Walleye Capital LLC Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Walleye Capital LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 248,288 shares of the biopharmaceutical company’s stock, valued at approximately $4,936,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Dimensional Fund Advisors LP raised its holdings in shares of Catalyst Pharmaceuticals by 9.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock valued at $46,479,000 after buying an additional 263,099 shares during the last quarter. Pacer Advisors Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 130,918.8% in the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after buying an additional 2,965,310 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Catalyst Pharmaceuticals by 15.2% in the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after buying an additional 287,300 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 4.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company’s stock valued at $23,215,000 after buying an additional 50,804 shares during the last quarter. Finally, Mesirow Institutional Investment Management Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 29.9% in the second quarter. Mesirow Institutional Investment Management Inc. now owns 934,234 shares of the biopharmaceutical company’s stock valued at $14,471,000 after buying an additional 215,130 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several analyst reports. Truist Financial increased their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 8th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target for the company. Finally, Citigroup increased their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $31.14.

Insiders Place Their Bets

In other news, Director Molly Harper sold 17,500 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Trading Down 1.2 %

Shares of CPRX opened at $22.07 on Monday. The firm’s 50-day moving average is $21.26 and its two-hundred day moving average is $18.79. Catalyst Pharmaceuticals, Inc. has a twelve month low of $13.00 and a twelve month high of $24.27. The firm has a market capitalization of $2.63 billion, a P/E ratio of 18.70, a PEG ratio of 3.40 and a beta of 0.75.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.